Anthra Valstar Recommended For Bladder CIS When Surgery Contraindicated
Executive Summary
Anthra's Valstar (intravesical valrubicin) should be approved for use by patients with carcinoma in situ of the bladder for whom bladder removal is contraindicated, FDA's Oncologic Drugs Advisory Committee decided during its Sept. 1 meeting.